-+ 0.00%
-+ 0.00%
-+ 0.00%

Definium Therapeutics to present Phase 3 Panorama topline data for DT120 in generalized anxiety disorder Sept. 14

PUBT·09/13/2026 21:00:19
Listen to the news
Definium Therapeutics to present Phase 3 Panorama topline data for DT120 in generalized anxiety disorder Sept. 14
  • Definium Therapeutics scheduled a Sept. 14, 2026 webcast to discuss topline results from its Phase 3 Panorama study in generalized anxiety disorder.
  • Results have not yet been presented; the company plans to release the topline readout during the event.
  • The update will cover Panorama, the second Phase 3 trial of DT120 (lysergide) orally disintegrating tablet in adults with the condition.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609131700BIZWIRE_USPR_____20260913_BW999570) on September 13, 2026, and is solely responsible for the information contained therein.